Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A phase II trial (CTEP 7190/Mel47)

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3611-3620

  Slingluff, Craig L ^a   Petroni, Gina R ^a   Molhoek, Kerrington R ^b   Brautigan, David L ^a   Chianese Bullock, Kimberly A ^a   Shada, Amber L ^a   Smolkin, Mark E ^a   Olson, Walter C ^a   Gaucher, Alison ^a,f   Chase, Cheryl Murphy ^a   Grosh, William W ^a   Weiss, Geoffrey R ^a   Wagenseller, Aubrey G ^a   Olszanski, Anthony J ^c   Martin, Lainie ^c   Shea, Sofia M ^a   Erdag, Gulsun ^d,g   Ram, Prahlad ^e   Gershenwald, Jeffrey E ^e   Weber, Michael J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b OpenQ   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f IQVIA   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD4 ANTIGEN; LACTATE DEHYDROGENASE; S6 KINASE; TEMSIROLIMUS; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; B RAF KINASE; GUANOSINE TRIPHOSPHATASE; KI 67 ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; PHOSPHOPROTEIN; RAPAMYCIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALLOIMMUNITY; ANOREXIA; ARTICLE; BRAF; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CD4+ FOXP3+ CELL; CELL PROLIFERATION; CHILL; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOLOGICAL MONITORING; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOENCEPHALOPATHY; LYMPHOCYTE; LYMPHOCYTOMA; LYMPHOCYTOPENIA; MALE; MELANOMA; MELANOMA CELL; MITOSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NRAS; ONCOGENE; OPPORTUNISTIC INFECTION; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN MICROARRAY; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; RIGOR; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; WEIGHT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BIOPSY; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; KI-67 ANTIGEN; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; SIROLIMUS; TREATMENT OUTCOME;

EID: 84879847151     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3919     Document Type: Article

References (39)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
2. Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol 2011;223:241-50.
3. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003;3:371-7. (Pubitemid 36908940)
4. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-10. (Pubitemid 39331010)
5. Molhoek KR, Shada AL, Smolkin M, Chowbina S, Papin J, Brautigan DL, et al. Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res 2011;21:274-84.
6. Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8:851 - 64.
7. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CL Jr. Human melanoma cytolysis by combined inhibition of mTOR and VEGF/VEGFR-2. Cancer Res 2008;68:4392-7.
8. Molhoek KR, Erdag G, Rasamny J, Murphy C, Deacon D, Patterson JW, et al. VEGFR-2 expression in human melanoma: Revised assessment. Int J Cancer 2011;129:2807-15.
9. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8. (Pubitemid 41170233)
10. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14:2367-76. (Pubitemid 47174913)
11. Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS ONE 2012;7:e38364.
12. Valmori D, Tosello V, Souleimanian NE, Godefroy E, Scotto L, Wang Y, et al. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4 T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4 T cells. J Immunol 2006;177:944-9. (Pubitemid 44036595)
13. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005;56:47-60. (Pubitemid 41278645)
14. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C. Rapamycin specifically interferes with GMCSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003;101:1439-45. (Pubitemid 36182518)
15. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996;14:483-510. (Pubitemid 26130192)
16. Uss E, Yong SL, Hooibrink B, van Lier RA, ten Berge IJ. Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation 2007;83:1098- 106.
17. Turner AP, Shaffer VO, Araki K, Martens C, Turner PL, Gangappa S, et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011;11:613- 8.
18. Ferrer IR, Wagener ME, Robertson JM, Turner AP, Araki K, Ahmed R, et al. Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8 +T cell responses. J Immunol 2010;185: 2004-8.
19. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-12.
20. Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, et al. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 2012;1:191-9.
21. Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer 2012;130:857-64.
22. Mulligan JK, Rosenzweig SA, Young MR. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother 2010;33:126-35.
23. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, et al. The effect of anti-VEGF therapyonimmature myeloid celland dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57:1115-24.
24. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics 2007;23:1986- 94.
25. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011;30:4567 -77.
26. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005;4:346-55. (Pubitemid 40590555)
27. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 2010;70:6704-14.
28. Slingluff CL Jr, Petroni GR, Olson W, Czarkowski AR, Grosh WW, Smolkin M, et al. Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008;26:4973-80.
29. Molhoek KR, McSkimming CC, Olson WC, Brautigan DL, Slingluff CL Jr. Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother 2009;58:867-76.
30. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011;29:2924- 32.
31. Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 2010;116:4122-9.
32. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40:310- 22.
33. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 2006;25:6373- 83.
34. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-58. (Pubitemid 37045363)
35. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol 2009;29:1172-8.
36. Schittek B, Psenner K, Sauer B, Meier F, Iftner T, Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 2007;120:2110-8. (Pubitemid 46555847)
37. Hiscutt EL, Hill DS, Martin S, Kerr R, Harbottle A, Birch-Machin M, et al. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy. J Invest Dermatol 2010;130:2250-8.
38. Chen J, Abi-Daoud M, Wang A, Yang X, Zhang X, Feilotter HE, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2012;10:1330- 7.
39. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221. Institute